Clinical trials
Relapsed or Refractory Multiple Myeloma clinical trials
Below are recruiting relapsed or refractory multiple myeloma clinical trials, each written for real people, not researchers. We’re tracking 1,287 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06456827Recruiting
Bite force and bone changes after braces in different face types
This trial compares how bite force and bone turnover markers change during the retention phase (after braces) in people with high-angle and low-angle face types. It may help understand why some people have more relapse after braces.
Rohtak, HaryanaAges 18–45 - NCT06458257Recruiting
Stem cell transplant for high-risk AML with CEBPA mutation
This trial tests whether a stem cell transplant from a donor can help people with a specific type of acute myeloid leukemia (AML) that has a high risk of coming back. It is for patients who have the CEBPA gene mutation and other high-risk features.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06470321Recruiting
Predictors of nicotine relapse in smokers
This study looks at factors that might predict whether someone will start smoking again after quitting. It is for adults who smoke daily, want to quit, and are not on any medications.
NicosiaAges 18–60 - NCT05748171RecruitingPhase 2
Testing inotuzumab for children with early ALL relapse
This Phase 2 study tests inotuzumab ozogamicin (InO), a cancer medicine, in children aged 1 to under 18 with a first relapse of ALL. It aims to find out how well and safely the medicine works when the leukemia comes back early.
ViennaAges 1–17 - NCT06487624RecruitingPhase 1
Study of HCB301 for advanced solid tumors and Hodgkin lymphoma
This trial tests a new drug called HCB301, which targets proteins that help cancer hide from the immune system. It is for people with advanced solid tumors or classical Hodgkin lymphoma who have tried other treatments without success.
Greenville, South CarolinaAges 18 years+ - NCT06492954RecruitingPhase 1
Testing atezolizumab with radiation and surgery for lung-only osteosarcoma
This trial tests whether combining an immunotherapy drug (atezolizumab) with focused radiation and surgery can help people whose osteosarcoma has come back only in the lungs. It aims to see if this approach is safe and may improve outcomes.
Atlanta, GeorgiaAges Up to 50 years - NCT06497361RecruitingEarly Phase 1
PRG-2311 for hard-to-treat lupus nephritis and IgG4 disease
This trial tests a new treatment called PRG-2311 for people with lupus nephritis or IgG4-related disease that has not responded to standard therapies. The treatment uses a type of immune cell therapy (CAR-T) to try to control the disease.
Wuhan, HubeiAges 18 years+ - NCT06497387RecruitingEarly Phase 1
PRG-1801 for stubborn lupus kidney and IgG4 disease
This trial tests a new treatment called PRG-1801 for people with lupus nephritis (kidney inflammation from lupus) or IgG4-related disease that has not improved with standard treatments. The treatment uses your own immune cells to target and calm the disease.
Wuhan, HubeiAges 18 years+ - NCT06498479RecruitingPhase 3
Comparing a new drug to topotecan for relapsed small cell lung cancer
This trial tests a new drug called HS-20093 against a standard drug (topotecan) for people with small cell lung cancer that has returned after initial treatment. The goal is to see which drug works better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06504290RecruitingPhase 1
Safety study of VV119 for healthy adults and people with schizophrenia
This trial tests if a new drug called VV119 is safe and how it works in the body. It is for healthy volunteers and for people who have had schizophrenia for at least a year and are currently having worsening symptoms.
Beijing, Beijing MunicipalityAges 18–65 - NCT06506149Recruiting
Microwave ablation for relapsed Graves' disease
This study tests if microwave ablation (a heat-based treatment) can help people whose Graves' disease returned after medication. It is a non-surgical option that may avoid lifelong medication or surgery.
Hong KongAges 18 years+ - NCT06508216RecruitingPhase 1/Phase 2
New drug combo for early relapsed triple-negative breast cancer
This trial tests experimental drugs for people with triple-negative breast cancer that came back within 12 months of finishing initial treatment. The goal is to see if these drugs are safe and can shrink or slow the cancer.
VillejuifAges 18 years+ - NCT06532084RecruitingPhase 2
Sorafenib to prevent relapse after stem cell transplant
This trial tests whether the drug sorafenib can prevent blood cancer from returning after a stem cell transplant. It is for people who had a special combination of chemotherapy (bendamustine and cyclophosphamide) during their transplant and are at high risk for relapse.
Saint PetersburgAges 18–75 - NCT06585514RecruitingPhase 1/Phase 2
CAR T-cell therapy for hard-to-treat lupus
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
Beijing, Beijing MunicipalityAges 3–65 - NCT06591429Recruiting
A study on hidden inflammation in multiple sclerosis
This study uses brain scans to look for hidden inflammation in people with multiple sclerosis who have not yet started a strong treatment. It aims to understand how this inflammation affects the disease and to help guide future therapies.
St Louis, MissouriAges 18 years+ - NCT07007195RecruitingEarly Phase 1
Smart smell app to help you quit smoking
This study tests a smartphone app that uses your sense of smell to help you quit smoking. You'll use nicotine replacement therapy (like patches or gum) and the app to avoid relapse.
Houston, TexasAges 18 years+ - NCT06609369RecruitingPhase 2
Sleep and smoking relapse study
This study tests whether improving sleep can help people quit smoking and avoid relapse. It uses brain scans, a quitting medication, and counseling.
New Haven, ConnecticutAges 18–65 - NCT06613217RecruitingPhase 1
Oral PCLX-001 for relapsed or refractory AML
This trial tests an oral drug called PCLX-001 for people with acute myeloid leukemia (AML) that has come back or not responded to previous treatments. The goal is to see if the drug is safe and can help control the leukemia.
Houston, TexasAges 18 years+ - NCT06613334Recruiting
Voice recordings to predict schizophrenia relapse
This study tests whether voice recordings can help predict when someone with schizophrenia might have a relapse. It is for people who are stable now and take certain medications.
Paris, ParisAges 18–60 - NCT06618755Recruiting
Staying sober after detox: a coaching study
This study tests if motivational interviews after hospital detox help people with alcohol use disorder stay completely sober for one year. It might help you if you are committed to full abstinence and have a phone available.
MontpellierAges 18 years+ - NCT06625970RecruitingPhase 3
Darolutamide and high-dose radiation for high-risk prostate cancer
This trial tests a combination of a hormone therapy pill (darolutamide) and a high-dose, precise form of radiation for men with localized prostate cancer that has high-risk features of coming back. The goal is to see if this approach is more effective than standard treatment.
BrestAges 18–80 - NCT06643585RecruitingPhase 3
Comparing T-DXd to standard therapy for molecular relapse in early breast cancer
This trial compares a new drug called Trastuzumab-Deruxtecan (T-DXd) to standard treatment for people with early breast cancer whose cancer has come back at a molecular level (detected by a blood test) but hasn't spread to other parts of the body. The goal is to see if T-DXd can prevent the cancer from returning.
UlmAges 18–75 - NCT06649253Recruiting
CD9 Gene and Relapse in Childhood B-ALL Study
This study looks at how a gene called CD9 might affect relapse in children with B-ALL. It involves extra blood or bone marrow tests to understand why some children relapse.
AngersAges birth–17 years - NCT06649227RecruitingPhase 1
CD19 CAR-T cells for hard-to-treat AML
This study tests a new type of immunotherapy (CAR-T cells that target CD19) for adults with acute myeloid leukemia (AML) that has not responded to treatment or has come back. It aims to see if these CAR-T cells are safe and can help control the leukemia.
LilleAges 18 years+
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory multiple myeloma?
- Yes. Clin2 currently lists 1,287 recruiting relapsed or refractory multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.